Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. The move comes as the company continues to expand its contract development and manufacturing organization (CDMO) platform, positioning itself to better serve the growing demand for biologics and pharmaceutical manufacturing services.
Kuratz brings more than 30 years of leadership, supply chain, and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee a broad range of functions, including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is expected to enhance operational efficiency and resilience within Scinai's CDMO operations.
The appointment follows Scinai's expansion of its CDMO platform through the first-quarter 2026 acquisition of Recipharm Israel, which added a second development and manufacturing site in Yavne. Combined with Scinai's Jerusalem operations, the expanded platform now provides a comprehensive suite of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing.
"We are delighted to welcome Eran to our team," said a company spokesperson. "His extensive experience in supply chain and operational management will be instrumental as we integrate our newly acquired facilities and scale our CDMO services to meet the needs of our clients."
Scinai Immunotherapeutics is a biopharmaceutical company focused on the development of innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Additionally, Scinai owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
The strategic appointment of Kuratz highlights Scinai's commitment to strengthening its operational backbone as it expands its manufacturing footprint. By enhancing supply chain management and business processes, the company aims to improve efficiency, reduce costs, and ensure the highest quality standards for its clients. This is particularly critical as the CDMO market becomes increasingly competitive and clients demand faster turnaround times and more reliable supply chains.
With the integration of the Yavne site, Scinai is well-positioned to offer end-to-end services from early-stage development to commercial manufacturing. The company's expanded capabilities are expected to attract a wider range of clients, including emerging biotech firms and established pharmaceutical companies seeking specialized manufacturing expertise.
For more information about Scinai Immunotherapeutics and its CDMO services, visit https://ibn.fm/d9ktl.
